Arrival to the Embassy of France

Alexandre Mebazaa (Paris, FRA) on behalf of the scientific committee

Moderated by Susanna Price (London, GBR) & Hannah Schaubroeck (Ghent, BEL)

8:40 AM - 8:50 AM Standardized definition for research from Shock Academy Research Consortium Mitchell Krucoff (Durham, USA)

8:50 AM - 9:00 AM Update on shock phenotyping Jacob Jentzer (Rochester, USA)

9:00 AM - 9:10 AM Trial design in Refractory CS: what is special? Mattia Arrigo (Zurich, SUI)

9:10 AM - 9:20 AM Informed consent in CS clinical trials in the United States Anu Lala (New York City, USA)

9:20 AM - 9:30 AM Informed consent in CS clinical trials in Europe Janine Pöss (Leipzig, GER)

9:30 AM - 9:40 AM ECLS Shock ended; what we learnt: on trial design Holger Thiele (Leipzig, GER)

9:40 AM - 9:50 AM ECLS Shock ended; what we learnt: on trial conduction Uwe Zeymer (Ludwigshafen, GER)

9:50 AM - 10:20 AM Panel discussion with the above as well as FDA, EMA, PDMA and NIH representatives & more.

In the lobby

Moderated by Alessandro Sionis (Barcelona, ESP) & Erin Bohula (Boston, USA)

10:40 AM - 10:45 AM COCCA Armand Mekontso Dessap (Paris, FRA)

10:45 AM - 10:50 AM DanGer shock Jacob Møller (Odense, DEN)

10:50 AM - 10:55 AM Hypo-ECMO Bruno Levy (Nancy, FRA)

10:55 AM - 11:00 AM ECMO-IABP Pascal Leprince (Paris, FRA)

11:00 AM - 11:05 AM Recover IV: what makes the design special Navin Kapur (Boston, USA)

11:05 AM - 11:10 AM Iso-Shock Mir Babar Basir (Detroit, USA)

11:10 AM - 11:15 AM IV-cangrelor STEMI schock Sarah Gorgis (Cleveland, USA)

11:15 AM - 11:45 AM Panel discussion with the above as well as FDA, EMA, PDMA and NIH representatives & more.

Moderated by George Sopko (NIH, USA) & Carolyn Rosner (Falls Church, USA)

11:45 AM - 11:55 AM DOREMI 2 Benjamin Hibbert (Ottawa, CAN)

11:55 AM - 12:05 PM Clinical endpoints to use PCZ in clinical trials: learnings from pre-clinical models of shock Feriel Azibani (Paris, FRA)

12:05 PM - 12:15 PM Biotherapies Mahir Karakas (Hamburg, GER)

12:15 PM - 12:40 PM Panel discussion with the above as well as FDA, EMA, PDMA and NIH representatives & more.

In the Lobby

Moderated by Harriette Van Spall (Hamilton, CAN) & Janine Pöss (Leipzig, GER)

1:30 PM - 1:40 PM Good start of AHA shock survey David Morrow (Boston, USA)

1:40 PM - 1:50 PM European survey is needed Nadia Aissaoui (Paris, FRA)

1:50 PM - 2:00 PM Update from The Cardiogenic Shock Working Group (CSWG) Registry Navin Kapur (Boston, USA)

2:00 PM - 2:10 PM Device and surgery Pascal Leprince (Paris, FRA)

2:10 PM - 2:20 PM Cardiogenic Shock: sex specific differences Vanessa Blumer (Cleveland, USA)

2:20 PM - 2:30 PM PAC-CS trial Shashank Sinha (Falls Church, USA)

2:30 PM - 2:35 PM FDA perspective Mauro Moscucci (FDA, USA)

2:35 PM - 2:40 PM EMA perspective Maciej Kostrubiec (EMA, POL)

2:40 PM - 2:45 PM PDMA perspective PDMA

2:45 PM - 2:50 PM NIH perspective George Sopko (NHLBI, USA)

2:50 PM - 3:45 PM Panel discussion with the above & more.

In the lobby

Moderated by Mitchell Krucoff (Durham, USA), Pascal Leprince (Paris, FRA) & Stuart Spencer (London, GBR)

4:00 PM - 4:10 PM Investigator US perspective Navin Kapur (Boston, USA)

4:10 PM - 4:20 PM Investigator Europe perspective Holger Thiele (Leipzig, GER)

4:20 PM - 4:30 PM Investigator Japan perspective Naoki Sato (JPN)

4:30 PM - 4:40 PM Industry perspective Karine Bourgeois (4TEEN, GER)

4:40PM - 4:50 PM Industry perspective Chuck Simonton (Abiomed, USA)

4:50 PM - 5:00 PM Industry perspective Andres Beiras (Getinge, GER)

5:00 PM - 5:10 PM FDA perspective Kathleen Grunder (FDA, USA)

5:10 PM - 5:20 PM EMA perspective Maciej Kostrubiec (EMA, POL)

5:20 PM - 5:30 PM NIH perspective George Sopko (NHLBI, USA)

5:30 PM - 5:40 PM Patient’s perspective Rhonda Monroe (Charlotte, USA)

5:40 PM - 6:15 PM Panel discussion with the above as well as NIH representative & more.

6:15 PM - 6:25 PM Take Home Messages David Baran (Ford Lauderdale, USA) & Susanna Price London (GBR)

6:25 PM - 6:30 PM Final words Alexandre Mebazaa (Paris, FRA)

In the restaurant